TREVISAN ROBERTO

Csermely, A., Borella, N., Turazzini, A., Pilati, M., Sheiban, S., Bonadonna, R., et al. (2026). Different Times for Different Metrics: Predicting 90 Days of Intermittently Scanned Continuous Glucose Monitoring Data in Subjects With Type 1 Diabetes on Multiple Daily Injection Therapy. Findings From a Multicentric Real-World Study. JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY, 20(3 (May 2026)), 761-774 [10.1177/19322968241308564]. Detail

Candido, R., Buzzetti, R., Consoli, A., Irace, C., Torre, E., Trevisan, R., et al. (2026). Once-weekly administration of insulin in the real-world management of type 2 diabetes. A Delphi-like consensus. ACTA DIABETOLOGICA, 63(2), 313-323 [10.1007/s00592-025-02619-8]. Detail

Borella, N., Ferramosca, A., Castagna, G., Ippolito, S., Ceresoli, S., Taverna, A., et al. (2025). Comparison of the night-time effectiveness in achieving glycemic targets in adults with type 1 diabetes of three advanced hybryd closed-loop systems. ACTA DIABETOLOGICA, 62(5), 763-771 [10.1007/s00592-024-02397-9]. Detail

Ciardullo, S., Dodesini, A., Muraca, E., Invernizzi, P., Trevisan, R., Perseghin, G. (2025). Readily Available Index of Insulin Sensitivity Is Associated with Metabolic Dysfunction-Associated Steatotic Liver Disease and Liver Fibrosis in Patients with Type 2 Diabetes. DIABETOLOGY, 6(6) [10.3390/diabetology6060050]. Detail

Castagna, G., Lepore, G., Borella, N., Trevisan, R. (2025). The high hourly overnight variability of insulin requirements as an explanation for the superiority of automated insulin delivery systems. DIABETES, OBESITY AND METABOLISM, 27(6 (June 2025)), 3512-3514 [10.1111/dom.16319]. Detail